Compare AngloGold Ashanti Limited (AU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Sanofi SA — how do they compare? AngloGold Ashanti Limited trades at $98.53 (market cap $49.28B), while Sanofi SA trades at $43.44 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.1× AngloGold Ashanti Limited's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| AU | SNY | |
|---|---|---|
Market Cap | $49.28B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $52.34 |
52-Week Low | $52.15 | $41.33 |
Enterprise Value | $48.29B | $124.19B |
Dividend Yield | 4.64% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.25, up 1.07% today, with a bullish technical signal from moving averages but overbought RSI readings. Strong fundamentals include a 26.64% net margin for 2025, robust free cash flow growth, and a $2 billion buyback program. Recent Q2 2026 earnings beat expectations, though Q4 2025 and Q2 2026 were misses. Analyst consensus is bullish with a $120.33 price target, and institutional buying has been noted in recent filings.
Outlook remains positive due to high gold prices, production growth, and shareholder returns, but risks include operational disruptions, inflation pressures, and volatile gold markets. The stock offers value with a P/E of 13.06 and strong profitability, yet investors should monitor cost inflation and geopolitical factors affecting mining operations.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
